Sign in
Not yet recruitingPhase 2

A study to learn about the effects and safety of LIB-01 in healthy adults and participants with erectile dysfunction

Key facts

Who runs it
Dicot Pharma AB
Where
Sweden4 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 2
People taking part
115 people, planned
Starts
30 Nov 2026
Expected to end
16 Nov 2027
Type of study
Interventional
Record updated
18 November 2026

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part
Show the full registry criteria (2)Hide the full registry criteria

Who can take part

  • Healthy men will take part in Part 1 if they are aged between 18 and 65 years, weigh at least 50 kgs, are non-smokers within 3 months before joining this part, and are willing to use condoms from the start of treatment to 2 days after treatment or not engage in unprotected sex. Men with ED will take part in Part 2 if they are aged between 25 and 70 years, have a stable heterosexual relationship for at least 6 months, are willing to be sexually active at least once a week and use condoms from the start of treatment to 2 days after treatment or not engage in unprotected sex, and have a score below a certain level on a questionnaire that measures erectile functioning of men. For the full list of the inclusion criteria please refer to Protocol section 4.2

Who cannot take part

  • Participants will be assessed to see if they have any conditions which might exclude them from participating, could interfere with the trial, or pose an unacceptable risk. Participants to whom any of the following applies will be excluded from the study: 1. Part 1: Multiple Dose Safety Cohort in Healthy Participants Exclusion Criteria 2. Part 2: Phase 2b Efficacy Study Exclusion Criteria For the full list of the exclusion criteria please refer to Protocol section 4.3

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sex
  • Erectile dysfunction

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Part 1: To evaluate the safety and tolerability of repeated administrations of LIB-01 oral tablets up to 100 mg daily doses in healthy participants

Read full original descriptionShow less

Part 2: To evaluate the efficacy of repeated administrations of LIB-01 oral tablets in the treatment of ED for all active treatment groups pooled vs. placebo

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A phase 2b, randomized, double-blind, parallel, and placebo-controlled trial investigating efficacy and safety of LIB-01 in erectile dysfunction including an initial safety cohort in healthy adult participants
Criteria questions
Built from 2026-525955-98-00, who can take part
Record updated
18 November 2026